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M A J O R A R T I C L E
Factors Associated With Viral Rebound in
HIV-1-Infected Individuals Enrolled in
a Therapeutic HIV-1 gag Vaccine Trial
Jonathan Z. Li,1,2 Zabrina L. Brumme,3,4 Chanson J. Brumme,3 Hongying Wang,5 John Spritzler,5 Michael N. Robertson,6
Michael M. Lederman,7 Mary Carrington,3,8 Bruce D. Walker,2,3,9 Robert T. Schooley,10 and Daniel R. Kuritzkes,1,2 for the
AIDS Clinical Trials Group A5197 Study Team
1Section of Retroviral Therapeutics, Brigham and Women's Hospital, Boston, Massachusetts; 2Harvard Medical School, Boston, Massachusetts; 3Ragon
Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts; 4Simon Fraser
University, Burnaby, British Columbia, Canada; 5Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts;
6Merck Research Laboratories, North Wales, Pennsylvania; 7Division of Infectious Diseases, Case Western Reserve University, Cleveland, Ohio; and
8Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, Inc., NCI-Frederick, Maryland; 9Howard Hughes Medical
Institute, Chevy Chase, Maryland; and 10Division of Infectious Diseases, University of California-San Diego, La Jolla
Background. Human immunodeficiency virus type 1 (HIV-1) vaccines directed to the cell-mediated immune
system could have a role in lowering the plasma HIV-1 RNA set point, which may reduce infectivity and delay
disease progression.
Methods. Randomized, placebo-controlled trial involving HIV-1-infected participants who received a recombi-
nant adenovirus serotype 5 (rAd5) HIV-1 gag vaccine or placebo. Sequence-based HLA typing was performed for all
110 participants who initiated analytic treatment interruption (ATI) to assess the role of HLA types previously
associated with HIV prognosis. Plasma HIV-1 gag and pol RNA sequences were obtained during the ATI. Virologic
endpoints and HLA groups were compared between treatment arms using the 2-sample rank sum test. A linear
regression model was fitted to derive independent correlates of ATI week 16 plasma viral load (w16 PVL).
Results. Vaccinated participants with neutral HLA alleles had lower median w16 PVLs than did vaccinated
participants with protective HLA alleles (P 5 .01) or placebo participants with neutral HLA alleles (P 5 .02). Factors
independently associated with lower w16 PVL included lower pre-antiretroviral therapy PVL, greater Gag sequence
divergence from the vaccine sequence, decreased proportion of HLA-associated polymorphisms in Gag, and
randomization to the vaccine arm.
Conclusions. Therapeutic vaccination with a rAd5-HIV gag vaccine was associated with lower ATI week 16 PVL
even after controlling for viral and host genetic factors.
Clinical Trials Registration. NCT00080106.
A robust cell-mediated immune response is vital for
the resolution of acute infection with human
immunodeficiency virus type 1 (HIV-1) and long-term
control of disease progression [1–5]. HIV-1 vaccines
directed to the cell-mediated immune system could have
a role in lowering the plasma HIV-1 RNA set point [6],
which may reduce infectivity and delay disease pro-
gression.
AIDS Clinical Trials Group (ACTG) protocol A5197
was a randomized, placebo-controlled trial to test the
effect of a recombinant adenovirus serotype 5 (rAd5)
HIV-1 gag therapeutic vaccine on plasma viral load
(PVL) in participants undergoing an analytic treatment
interruption (ATI) [7]. A total of 110 participants un-
derwent a 16-week ATI after randomization in a 2:1
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ratio to receive 3 doses of either vaccine or placebo. Although
there was a trend toward a vaccine benefit, this difference failed
to reach statistical significance for the prespecified coprimary
ATI endpoints (PVL set point: mean of ATI week 12 and 16 PVL
and time-averaged area under the curve). However, a secondary
analysis based on PVL at ATI week 16 (w16 PVL) found that
HIV-1 RNA levels were 0.5 log10 lower in the vaccine arm [7, 8].
The influence of HLA class I alleles on viral evolution,
disease progression, and PVL is well known [9–14]. A number of
‘‘protective’’ alleles (HLA B*13, B*27, B*51, B*57, and B*5801)
are associated with lower levels of viremia, delayed disease
progression, and/or improved outcomes [10, 15–20]. ‘‘Un-
favorable’’ HLA alleles associated with accelerated disease pro-
gression include the HLA-B*35-Px variants (B*3502, 3503, 3504,
or 5301) [21, 22]. In this analysis, we describe the distribution of
HLA alleles in ACTGA5197 and explore their impact on the w16
PVL response to a rAd5 HIV-1 gag vaccine.
This vaccine induced significant CD41 and CD81 HIV-
specific T cell responses [7]. In addition to HLA and T cell
activation, other factors that may play a role in vaccine effec-
tiveness and viral rebound include pre-antiretroviral therapy
(ART) PVLs [23–25], CD41 T cell counts [23, 24], HLA-
associated viral polymorphisms [14], preexisting Ad5 antibody
titers [26], and sequence similarity of patient virus to the vaccine
[27]. Using a hypothesis-driven approach, we created a multiple
linear regression model to identify factors independently corre-
lated with virologic rebound. Because the more robust vaccine
effect was not noted until ATI week 16, we focused our analysis
on the w16 PVL outcome.
METHODS
Patients and Study Design
Study design and patient inclusion criteria for ACTG A5197
have been described elsewhere [7]. Eligible participants were
receiving ART and had CD41 cell counts >500/mm3, plasma
HIV-1 RNA levels <50 copies/mL with a history of PVL <500
copies/mL for 24 months prior to enrollment, and screening
serum Ad5 antibody titers <200 units/mL. Participants were
stratified at randomization by their highest pre-ART PVL
(,30,000 copies/mL, > 30,000 copies/mL, or unknown).
Participants received a replication-defective rAd5 vaccine con-
taining an HIV-1 gag insert or placebo at weeks 0, 4, and 26
(step I). Starting at week 39, 110 participants (n 5 73 vaccine,
n5 37 placebo) underwent a 16-week ATI (step II). Participants
were encouraged to restart ART with any signs of immunode-
ficiency, for HIV-1 RNA .300,000 copies/mL at 3 consecutive
study visits, or if the CD41 cell count fell below 300 cells/mm3 at
2 consecutive visits or to ,50% of baseline. All participants
who entered the ATI were included in this analysis. ‘‘Dropouts’’
were defined as those who entered step II but did not complete
the 16-week ATI. Participants dropped out of step II mainly as
a result of reinitiation of ART for one of the reasons stated
above, adverse events, or patient preference.
HLA Typing
HLA class I typing was performed in accordance with the
sequence-specific oligonucleotide probing and sequence-based
typing protocols recommended by the 13th International His-
tocompatibility Workshop (http://www.ihwg.org). Protective
HLA alleles were defined a priori as HLA B*13, B*27, B*51, B*57,
and B*5801. Unfavorable HLA alleles were defined as the HLA-
B*35-Px variants (B*3502, 3503, 3504), or B*5301. The protective
HLA group includes all individuals with at least 1 protective HLA
allele. Those without a protective HLA allele but with at least 1
unfavorable HLA allele were categorized in the unfavorable HLA
group. Participants with neither protective nor unfavorable HLA
alleles were categorized in the neutral HLA group.
Intracellular Cytokine Staining Assay for Interferon-g
Blood drawn at protocol-defined intervals was sent to Merck
Research Laboratories by overnight courier. Vaccine-induced
cell-mediated immune responses were evaluated by an
intracellular cytokine staining (ICS) assay as described elsewhere
[7, 28, 29]. Lymphocytes were exposed to Gag, Nef, Pol or mock
peptide pools for 18 hours. Interferon-c–producing CD41 and
CD81 T cells were detected with use of multiparameter flow
cytometry. Participants were categorized as responders to
a peptide pool when .400 interferon-c–producing cells per
million lymphocytes were observed and this response was at
least 3 times greater than the response to the mock peptide pool
(except for CD8 response to pol2, which required.500 per 106
interferon-c–producing cells and .4 times the response to the
mock peptide pool) [7, 29].
Viral Sequencing from Plasma and Sequence Analysis
For most participants, plasma viral sequences were analyzed at 2
time points: at the time of initial detectable viremia (in general,
ATI weeks 2–7) and at ATI week 16. Of the 110 participants who
entered ATI, 105 had plasma available from at least 1 ATI time
point. The Gag and reverse-transcriptase (RT) coding sequences
were amplified from plasma HIV-1 RNA by nested RT poly-
merase chain reaction using gene-specific primers. Population
sequencing was performed on an ABI 3730 automated DNA
sequencer (Applied Biosystems). Chromatograms were analyzed
using Sequencher (Genecodes). We calculated the number of
amino acidmismatches between the vaccine or consensus HIV-1
subtype B sequence and the patient-derived sequence. HLA-
associated polymorphisms in patient HIV-1 sequences were
determined from a published list [14] derived from an analysis
of.1200 chronically infected, treatment-naive individuals from
several cohorts (HOMER, ACTG 5142/5128, and Western
Australia [WAHCS]) using phylogenetically corrected methods
[30] and a q-value correction for multiple tests (q , .05). The
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proportion of HLA-associated Gag polymorphisms in patient
sequences was calculated by dividing the number of HLA-
associated Gag polymorphisms observed in that sequence by
the total number of amino acids in Gag that displayed an HLA-
associated footprint at the population level for all HLA
alleles expressed by the participant. The RT-coding region of pol
was analyzed for the presence of the M184V mutation, which
confers 3TC resistance. Laboratory assessments were performed
by individuals who were blinded to treatment assignments.
The sequences reported here have been deposited in GenBank
(accession nos. GU560900–GU561307).
Statistical Analysis
The distribution of HLA alleles between treatment arms and the
distribution of step II dropouts among the HLA groups were
analyzed using the Fisher exact test. A comparison of PVL set
point (log10 mean week 12 and 16 PVLs) between HLA groups
was performed with the stratified (by trial arm) 2-sample rank
sum test. Exact 2-sided P values and shift parameter estimates
were provided for all comparisons. A comparison of the w16
PVL between vaccine and HLA groups was performed with the
stratified (on protocol-defined strata) 2-sample rank sum test.
As specified in the original protocol [7], participants without an
HIV-1 RNA evaluation at either ATI week 12 or 16 of step II
were assigned the worst ranks. Rank was assigned in reverse
order of the length of time off ART. No adjustments were per-
formed for multiple comparisons. Note that the comparisons
presented here were conducted post hoc after viewing the data.
The distribution of the number of gag-specific CD41 in-
terferon-c–producing cells and responders among HLA groups
and vaccine arms was analyzed with the 2-sample Wilcoxon rank
sum test and Fisher exact test, respectively. The Spearman cor-
relation was used to determine the relationship between w16 PVL
and patient-to-vaccine (or consensus subtype B) amino acid se-
quence mismatches. The distribution of the number and pro-
portion of HLA-associated polymorphisms in Gag at ATI week
16 in different HLA groups was assessed with the Jonckheere-
Terpstra trend test. Univariate linear regression was used to de-
termine significant factors associated with the w16 PVL (observed
data only). Predictor variables with P , .1 were added to the
multiple linear regressionmodel. Study arm andHLA group were
added to the models irrespective of their univariate significance.
RESULTS
Distribution of HLA Alleles between Vaccine and Placebo Arms
Post hoc HLA typing of study participants revealed a significant
imbalance in the distribution of favorable and neutral HLA al-
leles between arms. Of the 37 participants randomized to the
placebo arm who entered the ATI, 6 (16%) were found to have
a favorable HLA allele and 27 (73%) had neutral HLA alleles. In
contrast, 32 (44%) of 73 participants in the vaccine arm who
entered the ATI possessed at least 1 favorable HLA allele and 36
(49%) were found to have neutral HLA alleles.
Association between HLA Alleles and PVL Set Point
Compared with those with protective or neutral HLA alleles, the
9 participants with unfavorable HLA alleles had elevated PVL
rebound during ATI and a higher dropout rate during step II. By
week 16, 3 (33%) of 9 individuals with an unfavorable HLA allele
had dropped out of that phase of the study and 2 others had
missed the week 16 PVLmeasurement, compared with 7 (7%) of
101 participants with protective or neutral HLA alleles (P5 .01).
Given the high dropout rate by ATI week 16, we performed an
analysis of the protocol-defined PVL set point and confirmed
that, compared with individuals with unfavorable HLA alleles,
participants with neutral HLA alleles had a 1.32 log10 lower PVL
(P5 .005) and those with protective HLA alleles had a 0.71 log10
lower PVL (P 5 .05) after adjusting for vaccine effect.
Viral Rebound in Participants with Neutral HLA Alleles
When participants were categorized as having protective, neu-
tral, or unfavorable HLA alleles, the observed vaccine benefit was
found predominantly among participants with neutral alleles
(Table 1). The w16 PVLs were significantly lower in vaccinated
participants with neutral HLA alleles than in those with pro-
tective HLA alleles (P 5 .01) or those with neutral HLA alleles
who received placebo (P 5 .02). The high dropout rate during
step II among individuals with unfavorable HLA alleles pre-
cluded a more detailed analysis in that group.
Association between Gag-specific CD41 IFN-g Response and
Viral Load
Participants with CD41 IFN-c responses to HIV-1 Gag at study
week 38 had a 0.73 log10 lower PVL at week 16 of the subsequent
ATI after adjusting for vaccine effect (P 5 .02). Vaccinated
participants with neutral HLA alleles had a higher median
Table 1. Plasma Human Immunodeficiency Virus Type 1 RNA
Levels at Week 16 of the Analytic Treatment Interruption
HLA group Pa
Treatment arm, median
PbVaccine Placebo
Protective .01 4.6 (n 5 32) 4.4 (n 5 6)
Neutral 4.0 (n 5 36) 4.5 (n 5 27) .02
Unfavorable 5.7 (n 5 5) N/A (n 5 4)
NOTE. Data are median log10 plasma HIV-1 RNA copies/mL, with the
number of participants contributing to the analysis shown in parentheses. The
median is calculated on the basis of the assumption that the missing values are
greater than the greatest observed value. When the number of missing values
is more than half the sample size, the median is reported as ‘‘N/A’’. Three of
the 4 participants in the placebo group with unfavorable HLA alleles did not
complete the week 16 evaluation, including 2 participants who met protocol-
defined criteria for reinitiation of ART prior to ATI week 16. NA, not applicable.
a Comparison of the vaccine/protective and vaccine/neutral subgroups.
b Comparison of the vaccine/neutral and placebo/neutral subgroups.
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number of Gag-specific CD41 IFN-c–producing cells at week 38
than did immunized participants with protective alleles or pla-
cebo recipients with neutral alleles (Table 2).
Association of Patient Virus Divergence with Viral Rebound
The number of predicted amino acid mismatches was calculated
between the vaccine Gag sequence and the earliest available
patient-derived HIV-1 sequence after ATI (median, 4 weeks).
These early sequences represent viral populations least likely to
have been shaped by vaccine-driven immune responses. Among
vaccine recipients, we found a significant inverse correlation be-
tween the number of amino acid mismatches and the w16 PVL
(Spearman q 5 –0.36; P 5 .007) (Figure 1a). Unexpectedly, we
found a significant inverse correlation in the placebo arm as well
(Spearman q 5 –0.60; P 5 .001) (Figure 1b). The number of
amino acid mismatches correlated with the number of HLA-
associated Gag polymorphisms (defined as in [14]) only in those
with protective HLA alleles (Spearman q 5 0.37; P 5 .03). No
association was detected between the number of amino acid
mismatches and the number of Gag-specific CD41 or CD81
IFN-c–producing cells at study week 38. These correlations
remained largely unchanged if the patient sequences were
compared with the consensus subtype B Gag sequence instead
of the vaccine (the vaccine shared 98% amino acid sequence
homology with the consensus subtype B Gag sequence). To
determine whether such a correlation existed outside of Gag,
amino acid mismatches between consensus subtype B and
patient-derived viral sequences were also calculated for RT. No
correlation was found between the number of amino acid
mismatches between patient virus and consensus RT sequence
and the w16 PVL (Spearman q 5 –0.04; P 5 .71).
HLA-associated Gag Polymorphisms in Plasma Virus
The number of HLA-associated polymorphisms in Gag was
determined by sequencing plasma HIV RNA from ATI week 16.
There was a significant difference in the number of poly-
morphisms by HLA group. Individuals with protective or neu-
tral HLA alleles had more HLA-associated polymorphisms in
Gag than did those with unfavorable HLA alleles (6 vs 2.5,
P , .001; and 5 vs 2.5, P 5 .009, respectively) (Figure 2a). The
distribution of polymorphisms was shifted from high to low in
the direction of protective, neutral, and unfavorable HLA
groups (Jonckheere-Terpstra test 1-sided P , .001). A similar
trend was found when the proportion of HLA-associated Gag
polymorphisms among HLA groups was compared (Figure 2b;
Jonckheere-Terpstra test 1-sided P 5 .03).
Factors Independently Associated with ATI Viral Load
Factors independently associated with a lower w16 PVL (n5 50)
(Table 3) included a lower pre-ART PVL (P , .001), a lower
proportion of HLA-associated polymorphisms in Gag
(P, .001), a higher number of amino acid mismatches between
vaccine and patient virus in Gag (P5 .002), and randomization
to the vaccine arm (P 5 .02). The sample available for the
multiple linear regression model was limited by missing data for
some participants, principally as a result of absence of pre-ART
viral load data or dropping out prior to ATI week 16. There were
no significant differences in the distribution of any of the factors
included in the regression models between participants included
or excluded from these analyses (data not shown). Presence of
Table 2. Number of log10 Gag-Specific CD41 IFN-g–Producing
Cells per Million Lymphocytes at Study Week 38 Categorized by
HLA Allele Grouping and Treatment Arm
Treatment arm, median [IQR]a
HLA group Pb Vaccine Placebo Pc
Protective 10 2.21 [6 0.70] (n531) 2.25 [6 0.43] (n55)
Neutral 2.40 [6 0.40] (n536) 2.11 [6 0.51] (n527) .003
Unfavorable 2.1 [6 0.51] (n55) 2.17 [6 1.40] (n54)
NOTE
a IQR, interquartile range.
b Comparison of the vaccine/protective and vaccine/neutral subgroups.
c Comparison of the vaccine/neutral and placebo/neutral subgroups.
Figure 1. Association between ATI week 16 virus load endpoint (log10
HIV-1 RNA copies/mL) and the number of amino acid mismatches
between vaccine and subject Gag sequences in the vaccine (A) and
placebo (B) arms.
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the M184V mutation was not significantly associated with w16
PVL (P 5 .60). Of the variables found to be significant in the
univariate analysis, week 38 Gag-specific CD41 interferon-c
response, Ad5 titer, and CD4 nadir did not reach statistical
significance in the multiple linear regression model.
DISCUSSION
In ACTG A5197, HIV-1–infected individuals who received
a rAd5 HIV-1 gag therapeutic vaccine had a 0.5 log10 lower PVL
after a 16-week ATI, compared with those who received placebo
[7, 8]. In this post hoc exploratory analysis, we analyzed factors
associated with vaccine response and identified variables asso-
ciated with viral rebound at ATI week 16. We found that the
vaccine effect on PVL was observed primarily in participants
with neutral HLA alleles; those with unfavorable HLA alleles
fared poorly regardless of study arm.
The beneficial effect of protective HLA alleles on PVL set
point has been described elsewhere [17, 31, 32]. In the STEP
trial, which used a rAd5 HIV-1 Gag-Pol-Nef vaccine, vaccine
recipients with protective HLA alleles had significantly lower
PVL set points after infection [33]. In the present study, vaccine-
associated reduction in w16 PVL was not observed in partic-
ipants with protective HLA alleles. A potential explanation may
be that in this chronically infected population, patients with
favorable HLA alleles had already developed maximal anti-Gag
immune responses, or HIV-1 had already adapted to evade those
responses so that little additional benefit was obtained from
vaccination [34]. For example, in studies of HLA-matched
transmission pairs, protective alleles were not associated with
lower set point PVL in the newly infected persons when HLA-
associated viral escape mutations were present [32, 35]. The
finding that the vaccine effect on w16 PVL was greatest in in-
dividuals with neutral HLA alleles was surprising. It may be that
such individuals elaborate suboptimal HIV-1–specific cell-me-
diated immune responses to the infecting virus and thus benefit
from a vaccine-induced boost in immunity. The relatively small
number of participants with an unfavorable HLA allele pre-
cludes broad generalizations, but the higher PVL set point in this
Figure 2. Number of HLA-associated Gag escape mutations (A) and
proportion of HLA-associated Gag polymorphic sites showing escape
mutations (B) per person by HLA group. The proportion of escape
mutations was calculated as the number of HLA-associated poly-
morphisms in a viral sequence divided by the total number of possible
HLA-associated polymorphic sites for each subject.
Table 3. Factors Independently Associated with log10 Human
Immunodeficiency Virus Type 1 RNA Levels at Analytic Treatment
Interruption Week 16 Using Observed Data Only
Variable P Coefficient (95% CI)
Pre-ART viral load, log10
copies/mL
,.001 0.53 (0.36–0.70)
Proportion of HLA-associated
escape mutations
,.001 1.83 (0.99–2.66)
Patient-vaccine amino acid
mismatches
.002 –0.03 (–0.05 to –0.01)
Vaccine arm assignment .02 –0.31 (–0.56 to –0.06)
NOTE. ART, antiretroviral therapy; CI, confidence interval.
Table 4. Expected and actual HLA phenotypic frequencies by
treatment arm and HLA group.
HLA group Vaccine arm Placebo arm
Expected Actual Expected Actual
Protective 30% (22/73) 44% (32/73) 31% (11/37) 16% (6/37)
Neutral 62% (45/73) 49% (36/73) 61% (23/37) 73% (27/37)
Unfavorable 8% (6/73) 7% (5/73) 8% (3/37) 11% (4/37)
NOTE. Expected phenotypic frequencies based on A5197 ethnic distribu-
tion and calculated from HLA alleleic frequencies of U.S.-based cohorts of
European Americans and African Americans (M. Carrington personal commu-
nication), and Hispanic and Asian Americans [1, 2].
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group is consistent with the higher risk of clinical progression
reported in previous studies [21, 22].
The chance imbalance of protective HLA alleles between
vaccine and placebo arms in this study raises a cautionary note.
On the basis of large studies of HLA allelic frequencies in US
populations [36, 37] and the ethnic makeup of the A5197 study
population, we determined the expected distribution of partic-
ipants within each HLA group by treatment arm (Table 4). Be-
cause the vaccine effect was seen predominantly in those with
neutral HLA alleles, the under representation of participants with
neutral HLA alleles in the vaccine arm likely resulted in an un-
derestimate of vaccine efficacy. The imbalance in HLA alleles in
the placebo arm did not seem to have a substantial effect on the
viral load outcome, because the participants with protective and
neutral HLA alleles had similar w16 PVL results. These results
suggest that HLA class I typing should be an integral part of the
analysis of vaccine trials designed to stimulate cell-mediated
immune responses. In certain circumstances, stratifying for
protective and/or unfavorable HLA alleles at randomization may
be appropriate. This concern is especially pertinent for small,
early-phase trials of preventive or therapeutic vaccines.
A strong CD4-mediated Gag-specific IFN-c response has been
associated with natural control of HIV-1 replication during
primary infection [38]. The strength of such responses correlates
inversely with plasma HIV-1 RNA levels in untreated individuals
[39]. Vaccination of HIV-1–infected participants with the rAd5
HIV-1 gag resulted in significantly increased HIV-specific CD41
and CD81 IFN-c activity [7]. In this study, vaccinated partic-
ipants with neutral HLA alleles tended to have a higher number
of Gag-specific CD41 IFN-c–producing cells and a higher pro-
portion of CD41 IFN-c responders, which in turn were associ-
ated with significantly lower w16 PVL. One potential explanation
of these results could lie in the finding that CD81 T cells lose the
capacity to proliferate during chronic infection but this function
is restored by vaccine-augmented CD41 T helper cells [40].
However, in the current study, CD41 IFN-c responses did not
predict w16 PVL in the multiple linear regression model. Addi-
tional analysis of other vaccine-induced cytokine responses may
clarify their role in determining PVL during postvaccination ATI.
Autologous HIV-1 peptides induce stronger HIV-1–specific
T cell responses than do consensus peptides [27]. We therefore
hypothesized that greater similarity between vaccine and patient-
derived Gag sequences would be associated with stronger T cell
responses, resulting in lower viral rebound during ATI. No as-
sociation was found, however, between the number of amino
acid mismatches and the number of Gag-specific CD41 or
CD81 IFN-c–producing cells immediately before treatment in-
terruption. Surprisingly, the number of Gag mismatches was
negatively correlated with w16 PVL in both vaccine and placebo
arms. No such correlation was found for RT. HIV-1 adapts to
host immune responses at the population level, and consensus
sequences reflect that adaptation [13]. Perhaps viruses that are
closest in sequence to the clade consensus have a fitness ad-
vantage; greater divergence from the consensus subtype B Gag
sequence could reflect greater immune pressure on the virus.
Although the number of Gagmismatches was correlated with the
number of HLA-associated Gag polymorphisms in participants
with protective HLA alleles, the number of Gag mismatches was
independently associated with lower w16 PVL on multivariate
analysis. In vitro fitness studies in acute and chronically infected
patients are needed to explore the meaning of this finding.
Mutations in epitopes targeted by HLA-restricted CD8
T lymphocytes may result in loss of viral fitness, but they also
represent viral escape from immunological control, and their
presence has been associated with higher PVL [32, 41–43]. In the
current study, we found that the proportion of HLA-associated
Gag polymorphisms was associated with higher w16 PVLs. This
result is consistent with a previous study that reported a modest
positive correlation between the proportion of escaped Gag sites
and PVL [43].
As a post hoc analysis, this study has a number of limitations.
The decision was made to use w16 PVL as the main outcome
measure because of the more robust vaccine effect when com-
pared with the protocol-defined endpoints. The small number
of participants included in the multivariate linear regression
model and in the study as a whole limits the generalizability of
the results. The main factor for excluding patients from the
model was a lack of information on pre-ART viral load, which
was known for only two-thirds of participants but was one of the
strongest predictors of viral rebound. This finding validates the
decision to stratify according to the highest pre-ART viral load
at randomization in the original clinical trial. No significant
differences were found between those individuals included and
excluded from the linear regression model. Despite these limi-
tations, in-depth analyses of HIV-1 vaccine trials are crucial in
identifying potential correlates of vaccine efficacy.
The ACTG A5197 study represents another step forward in
furthering our understanding of the immunological and viro-
logical factors important for control of HIV-1 infection. In the
exploratory analysis reported here, we identified a number of
factors associated with viral rebound during the ATI following
administration of a rAd5 HIV-1 gag vaccine. Importantly,
therapeutic vaccination was associated with lower ATI week 16
PVL even after controlling for these host and viral factors. Ad-
ditional analyses of ACTG A5197 and other therapeutic vaccine
trials may provide a deeper understanding of the interplay be-
tween the HLA-restricted, cell-mediated immune response and
the process by which HIV escape and virologic rebound occur.
Such insights will be crucial for the successful development of
therapeutic and preventative HIV vaccines.
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Erratum 
In “Factors Associated with Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 
gag Vaccine Trial,” by Li et al. (J Infect Dis. (2011) 203 (7): 976–983), the title of Table 2 was 
inadvertently changed and some data were incorrect due to errors made without the authors' 
knowledge. A corrected version of the table is shown below.  
Table 2.  
Number of log10 Gag-Specific CD4+ IFN-γ-Producing Cells per Million Lymphocytes at Study 
Week 38 Categorized by HLA Allele Grouping and Treatment Arm  
  
Treatment arm, median [IQR]
a
 
HLA group P
b
 Vaccine Placebo P
c
 
Protective .10 2.21 [± 0.70] (n=31) 2.25 [± 0.43] (n=5) 
 
Neutral 
 
2.40 [± 0.40] (n=36) 2.11 [± 0.51] (n=27) .003 
Unfavorable 
 
2.1 [± 0.51] (n=5) 2.17 [± 1.40] (n=4) 
 
 NOTE. 
a
IQR, interquartile range.  
 ↵b Comparison of the vaccine/protective and vaccine/neutral subgroups.  
 ↵c Comparison of the vaccine/neutral and placebo/neutral subgroups.  
 
